loading

INVITRO’S OCULAR IRRITECTION® REACHES FINAL STAGE OF OECD’S TEST METHOD ADOPTION

FOR IMMEDIATE RELEASE

CONTACT

 

InVitro International   Contact: W. Richard Ulmer
330 E. Orangethorpe Ave., Ste. D   (800) 246-8487
Placentia, CA 92870    http://www.invitrointl.com

 

Placentia, CA – November 15, 2017

Last week, at the annual meeting of the Organization for Economic Common Development (OECD) Expert Group on Skin and Eye Irritation Test Methods in Paris, InVitro International and its long-time Italian in vitro testing partner, INT.E.G.RA, received final OECD Expert Group on Skin and Eye Irritation Test Methods acceptance of Ocular Irritection®.  The OECD is generally viewed as the world’s foremost regulatory authority on in vitro test methods.

The company plans to move forward immediately to compose a Test Guideline (TG) document for submission to the OECD. The TG will make our test method both clear and available to all laboratories that wish to use the Ocular Irritection® test.  Completion of a TG can take several months to more than one year.

InVitro CEO & President, W. Richard Ulmer, said: “This nearly global level of regulatory support for a non-mammalian (plant protein) test technology not only means much to InVitro, but also could possibly encourage more innovative in vitro test methods to be developed as well. We continue to be very enthusiastic about the future for non-animal testing on a global basis. Ocular Irritection® is the only such method with OECD acceptance which can be shipped anywhere in the world with significant remaining shelf life for its laboratory users.”

This release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward looking statements. These risks and uncertainties include, but are not limited to: acceptance of the Company’s technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.

 

 

Posted on Categories News

Leave a Reply

Your email address will not be published. Required fields are marked *